Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“SCLC therapeutic landscape is rapidly changing, with T-cell engagers, ADCs and bi-specifics moving fast to earlier lines of treatment and challenging the current treatment paradigm.
Thrilled to discuss the landscape with KOLs Solange Peters and Nicolas Girard in a brain-storming discussion”
Other articles featuring Dr. Mountzios on OncoDaily.
